评论：评估潜在的胶质瘤血清生物标志物及其未来应用。
Commentary: Evaluating potential glioma serum biomarkers, with future applications.
作者信息
Goutnik Michael, Lucke-Wold Brandon
机构信息
Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States.
出版信息
World J Clin Oncol. 2022 May 24;13(5):412-416. doi: 10.5306/wjco.v13.i5.412.
Abstract
Systemic inflammation within malignant glioma is a topic of ongoing significance. In this commentary, we highlight recent findings from Gandhi and discuss alternative approaches. We present a counter argument with findings that IL-6 markers are controversial. We highlight the potential benefit of looking at microRNAs and other biomarkers. Finally, we present ideas for future application involving differentiation between radiation necrosis and recurrence. The commentary is intended to serve as a catalyst for further scientific discovery.
摘要
恶性胶质瘤中的全身炎症是一个具有持续重要性的话题。在这篇评论中，我们强调了甘地的近期研究发现并讨论了替代方法。我们提出了一个反对观点，即白细胞介素-6标志物存在争议。我们强调了研究微小RNA和其他生物标志物的潜在益处。最后，我们提出了未来应用的想法，涉及放射性坏死和复发的鉴别。这篇评论旨在成为进一步科学发现的催化剂。
相似文献
1
Commentary: Evaluating potential glioma serum biomarkers, with future applications.评论：评估潜在的胶质瘤血清生物标志物及其未来应用。
World J Clin Oncol. 2022 May 24;13(5):412-416. doi: 10.5306/wjco.v13.i5.412.
2
Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.用于恶性胶质瘤治疗的白细胞介素-13受体导向细胞毒素：从实验室到临床应用
J Neurooncol. 2003 Oct;65(1):37-48. doi: 10.1023/a:1026242432647.
3
Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study.术前炎症标志物对胶质瘤患者的诊断价值：一项多中心队列研究。
J Neurosurg. 2018 Sep;129(3):583-592. doi: 10.3171/2017.3.JNS161648. Epub 2017 Nov 3.
4
Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.蛋氨酸正电子发射断层扫描在立体定向放射治疗后复发性脑肿瘤与放射性坏死的鉴别诊断中的应用——在恶性胶质瘤中的研究
Ann Nucl Med. 2004 Jun;18(4):291-6. doi: 10.1007/BF02984466.
5
Patterns of failure following surgical resection for malignant pleural mesothelioma.恶性胸膜间皮瘤手术切除后的失败模式。
Thorac Surg Clin. 2004 Nov;14(4):567-73. doi: 10.1016/j.thorsurg.2004.06.006.
6
Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.用于恶性胶质瘤治疗的白细胞介素-4-绿脓杆菌外毒素嵌合融合蛋白
J Neurooncol. 2003 Oct;65(1):15-25. doi: 10.1023/a:1026294416718.
7
Serum proteomics of glioma: methods and applications.胶质瘤的血清蛋白质组学：方法与应用
Expert Rev Mol Diagn. 2009 Oct;9(7):695-707. doi: 10.1586/erm.09.52.
8
Differentiation of Tumorigenic C6 Glioma Cells Induced by Enhanced IL-6 Signaling.增强型IL-6信号诱导致瘤性C6胶质瘤细胞的分化
Medicina (Kaunas). 2020 Nov 19;56(11):625. doi: 10.3390/medicina56110625.
9
Advanced multimodal imaging in differentiating glioma recurrence from post-radiotherapy changes.高级多模态成像在鉴别脑胶质瘤复发与放疗后改变。
Int Rev Neurobiol. 2020;151:281-297. doi: 10.1016/bs.irn.2020.03.009. Epub 2020 May 13.
10
Preoperative Hematologic Inflammatory Markers as Prognostic Factors in Patients with Glioma.术前血液学炎症标志物作为胶质瘤患者的预后因素
World Neurosurg. 2018 Nov;119:e710-e716. doi: 10.1016/j.wneu.2018.07.252. Epub 2018 Aug 6.
引用本文的文献
1
Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.利用外周血血浆的 FTIR-ATR 光谱区分胶质瘤中的 IDH 突变状态，表明存在明显的蛋白质淀粉样聚集痕迹。
BMC Cancer. 2024 Feb 16;24(1):222. doi: 10.1186/s12885-024-11970-y.
2
Emerging perspectives on RNA virus-mediated infections: from pathogenesis to therapeutic interventions.RNA病毒介导感染的新观点：从发病机制到治疗干预
World J Virol. 2023 Dec 25;12(5):242-255. doi: 10.5501/wjv.v12.i5.242.
3
Systematic Review of the Diagnostic and Clinical Utility of Salivary microRNAs in Traumatic Brain Injury (TBI).唾液 microRNAs 在创伤性脑损伤（TBI）中的诊断和临床效用的系统评价。
Int J Mol Sci. 2022 Oct 29;23(21):13160. doi: 10.3390/ijms232113160.
本文引用的文献
1
A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide.一种用于对接受放疗加同步及辅助替莫唑胺治疗的异柠檬酸脱氢酶野生型胶质母细胞瘤患者的预后进行分层的简单术前血细胞计数。
Cancers (Basel). 2021 Nov 18;13(22):5778. doi: 10.3390/cancers13225778.
2
Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients.用于评估初治胶质瘤患者全身炎症和生存情况的新型分子检测板
World J Clin Oncol. 2021 Oct 24;12(10):947-959. doi: 10.5306/wjco.v12.i10.947.
3
Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review.中性粒细胞-淋巴细胞比值作为预测脑胶质瘤肿瘤分级的预测因子的作用：系统评价。
Crit Rev Oncol Hematol. 2021 Jul;163:103372. doi: 10.1016/j.critrevonc.2021.103372. Epub 2021 May 29.
4
Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis.循环微小RNA作为胶质瘤患者有前景的诊断生物标志物：一项荟萃分析
Front Neurol. 2021 Feb 1;11:610163. doi: 10.3389/fneur.2020.610163. eCollection 2020.
5
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression.胶质母细胞瘤衍生的白细胞介素 33 调控炎症性脑肿瘤微环境，从而加速胶质母细胞瘤的进展。
Nat Commun. 2020 Oct 5;11(1):4997. doi: 10.1038/s41467-020-18569-4.
6
Biomarkers of Brain Damage Induced by Radiotherapy.放疗所致脑损伤的生物标志物
Dose Response. 2020 Jul 9;18(3):1559325820938279. doi: 10.1177/1559325820938279. eCollection 2020 Jul-Sep.
7
Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40.胶质瘤中的全身免疫调节：血浆白细胞介素-6、YKL-40及YKL-40基因变异的预后价值
Front Oncol. 2020 Apr 17;10:478. doi: 10.3389/fonc.2020.00478. eCollection 2020.
8
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.IDO1 和 TDO 通过 Kyn-AhR-AQP4 信号通路促进神经胶质瘤的恶性进展。
Signal Transduct Target Ther. 2020 Feb 21;5(1):10. doi: 10.1038/s41392-019-0103-4.
9
Circulating biomarkers in patients with glioblastoma.胶质母细胞瘤患者的循环生物标志物。
Br J Cancer. 2020 Feb;122(3):295-305. doi: 10.1038/s41416-019-0603-6. Epub 2019 Oct 31.
10
Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis.中性粒细胞与淋巴细胞比值对脑胶质瘤预后的影响：系统评价和荟萃分析。
World J Surg Oncol. 2019 Aug 31;17(1):152. doi: 10.1186/s12957-019-1686-5.
Zotero 插件